This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -44.44% and 9.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Best Momentum Stocks to Buy for July 15th
by Zacks Equity Research
TBPH, HGV, and SPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2024.
New Strong Buy Stocks for July 15th
by Zacks Equity Research
TEF, AY, CQP, TBPH, and VIRC have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2024.
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
by Zacks Equity Research
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
Here's Why You May Invest in Theravance (TBPH) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
by Zacks Equity Research
Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 52.63% and 0.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of -125% and 3.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
by Zacks Equity Research
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 175% and 0.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates
by Zacks Equity Research
Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of -65% and 1.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally
by Zacks Equity Research
Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.
Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 18.75% and 9.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?